Ranked by conviction, tracked by status. Closer to a private investment memo than a news feed, and unlike news it compounds. Updated June 2026.
Treated as charity, rare disease in Africa is really an underbuilt market, genuine unmet need, widening access pathways, and almost no competition. The moral framing has hidden a commercial one.
Watching: Section 21 named-patient programmes, orphan-drug designations, manufacturer access deals, and the first credible reimbursement signals.
The African Medicines Agency is quietly assembling something the continent has never had: a single regulatory market. Mutual recognition would collapse approval timelines and redraw who can reach patients.
Watching: AMA staffing and funding, treaty ratifications, mutual-recognition pilots, and which national regulators are genuinely ready.
East African trial infrastructure is maturing just as sponsors hit cost ceilings and demand more genetically diverse data. Two pressures, pointing the same way.
Watching: Site networks, ethics-committee harmonisation, remote-monitoring vendors, and investigator capacity.
Biologics and specialty therapies need cold chain and last-mile capability that barely exists here. The missing infrastructure is the investable thing.
Watching: Cold-chain capital, GDP licensing, regional hubs, and consolidation among distributors.
A shortage of radiologists and pathologists, near-universal smartphones, and a relatively open regulatory posture make Africa a natural home for assisted diagnostics, if it can get paid for.
Watching: WHO prequalification, reimbursement design, data-sovereignty rules, and local validation studies.
Frontier African debt was repriced as a block. The mispricing now sits in the names, quality issuers punished for problems that are not their own.
Watching: Eurobond spreads, local-currency yields, IMF programme progress, and restructuring precedents.
Localisation politics, AfCFTA and import-substitution pressure are pulling diagnostics and pharma manufacturing onshore. Whether it lasts will depend on demand, not sentiment.
Watching: Public-private partnerships, technology transfer, procurement guarantees, and quality-system readiness.
Reliable power is the precondition no health investment memo bothers to cost in, yet clinics, labs and cold chain all fail without it. The cheapest health intervention may be electrical.
Watching: Solar-plus-storage for facilities, financing structures, and energy-as-a-service providers moving into health.
Concessional and climate-linked capital is looking for bankable African projects, while health and resilience infrastructure is looking for capital. The two rarely meet because nobody packages the deal.
Watching: GCF and DFI windows, blended structures, first-loss facilities, and which intermediaries can actually originate.
Device and in-vitro diagnostic regulation across the continent is years behind pharma, and is now starting to formalise. Early movers who understand the rules before they harden gain a durable edge.
Watching: SAHPRA device licensing, regional IVD frameworks, reliance pathways, and conformity-assessment capacity.
Telemedicine adoption ran ahead of the rules that pay for it. The opportunity is not the app; it is the reimbursement and scheme-integration layer that turns usage into revenue.
Watching: Medical-scheme coverage decisions, HPCSA telehealth guidance, and employer-funded primary care models.
Early-phase and first-in-human work has stayed offshore, but sponsor cost pressure and growing local GCP capability are starting to question that default. A long-dated but high-value shift.
Watching: Phase 1 unit accreditation, ethics and regulatory readiness, sponsor pilots, and investigator training pipelines.
Solar and storage are now cheap enough that the question is no longer generation but productive use, powering clinics, cold chain, irrigation and processing. The asset is the load, not the panel.
Watching: Energy-as-a-service models, anchor offtakers, tax allowances, and financiers comfortable with distributed assets.
Water is treated as a utility problem when it is increasingly a health, agricultural and industrial-continuity problem. Securing it at facility and farm level is becoming a precondition for everything else.
Watching: On-site treatment and storage, financing structures, municipal failure patterns, and reuse technology.